17.28
0.11 (0.64%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | HUTCHMED (China) Limited | Bearish | Bearish |
Stockmoo Score
|
HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Mid Value |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Aia Group Ltd | 30 Jun 2024 | 315,439 |
| 52 Weeks Range | ||
| Median | 19.00 (9.95%) | |
| Total | 1 Hold | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Goldman Sachs | 01 Aug 2024 | 19.00 (9.95%) | Hold | 18.48 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 30 Aug 2024 | Announcement | HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China |
| 21 Aug 2024 | Announcement | HUTCHMED to Host Expert Call to discuss Immune Thrombocytopenia |
| 31 Jul 2024 | Announcement | HUTCHMED Reports 2024 Interim Results and Provides Business Updates |
| 03 Jul 2024 | Announcement | HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status |
| 26 Jun 2024 | Announcement | HUTCHMED to Announce 2024 Half-Year Financial Results |
| 24 Jun 2024 | Announcement | Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024 |
| 21 Jun 2024 | Announcement | HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda |
| 16 Jun 2024 | Announcement | HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |